Loading quotes...

Forecast

Buy	0
Hold	1
Sell	0

News Go to news feed

CEO resignation pushes Swedish Orphan Biovitrum stock

Swedish Orphan Biovitrum announced before trading that CEO Guido Oelkers will resign and take a position outside the company; his departure is planned no later than the end of January 2027. The share fell about 4.3% to 450.6 SEK as investors feared a classic key-man risk. The board immediately launched the search for a successor and stressed that operations, strategy and financial targets remain unchanged. The reaction comes despite strong fundamentals: the Q2 report on July 16 showed revenue growth of 29% and an adjusted EBITA margin of 35%, after which the full-year guidance was raised. » More on de.investing.com
Swedish Orphan Biovitrum Un announces quarterly results for Q2 2026

Swedish Orphan Biovitrum Un will publish results for the quarter ended June 30, 2026 on July 16, 2026. Seven analysts expect average EPS of $0.176 for the quarter versus $0.100 a year ago, and nine analysts forecast revenue to rise about 19.5% to an average of $763.1 million. For the current fiscal year, average analyst estimates are $0.964 earnings per share and $3.35 billion in revenue. » More on finanzen.net
Swedish Orphan Biovitrum Un announces results for quarter ended 30.06.2026

Swedish Orphan Biovitrum Un will present the results for the quarter ended 30.06.2026 on 16.07.2026. Analyst consensus sees earnings per share of 0.175 USD (+75% vs. prior year) and revenue of 770.9 million USD (+20.7% vs. prior year). For the current fiscal year analysts expect on average 0.966 USD earnings per share and revenue of 3.38 billion USD. » More on finanzen.net

Financials

In the last quarter, Swedish Orphan Bio had revenue of €761.54M and net profit of €196.14M

(EUR)	September 2026	YoY
Revenue	761.54M	9.01%
Gross profit	536.76M	572.75%
Net profit	196.14M	175.41%
EBITDA	344.21M	4.75%

Fundamentals

Metric	Value
Market capitalization	€14.17B
Number of shares	348M
52-week high/low	€43.68 - €31.08
Dividends	No
Beta	0.29
P/E ratio	26.24
PEG ratio	0.00
P/B ratio	3.84
P/S ratio	5.46

Company profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.